The remarkable social impact of clinical trials of COVID-19 drugs and vaccines

• Gonzalo Casino ^[1] ; Fèlix Bosch ^[2]
  1. [1] Universitat Pompeu Fabra

     Universitat Pompeu Fabra

     Barcelona, España

     
  2. [2] c Former Director, Dr. Antoni Esteve Foundation, Barcelona, Spain. d Lecturer, Faculty of Medicine, University of Vic-Central University of Catalonia, Vic, Spain
• Localización: Actualidad en farmacología y terapéutica, ISSN 1698-4277, Vol. 22, Nº. 1, 2024, págs. 13-14
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Research on COVID-19 was widely reported in journals and received wide media coverage.

    During the first year of the pandemic, 627 papers were published about clinical trials for COVID-19 drugs and vaccines. The three articles that had the greatest social impact (Altmetric Attention Score, AAS) evaluated the vaccines Gam-COVID-Vac, tozinameran, and ChAdOx1. The Lancet‘s publication of the Gam-COVID-Vac clinical trial had the highest AAS and the highest AAS of all articles ever published in this journal. The Lancet and Lancet Infectious Diseases were the only journals to publish papers on clinical trials about vaccines developed in non-Western countries.